Real World Study of VIEKIRAX (ombitasvir/paritaprevir/ritonavir) and EXVIERA (dasabuvir) With Or Without Ribavirin In Patients With Chronic Hepatitis C Virus Infection.

Trial Profile

Real World Study of VIEKIRAX (ombitasvir/paritaprevir/ritonavir) and EXVIERA (dasabuvir) With Or Without Ribavirin In Patients With Chronic Hepatitis C Virus Infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AMBER
  • Most Recent Events

    • 14 Apr 2018 According to results presented at The International Liver Congress 2018, this first real world experience study was carried-out in 2014-2015.
    • 14 Apr 2018 Results (n=202) of an analysis of two years follow-up focusing on risk of hepatocellur carcinoma development, presented at The International Liver Congress 2018.
    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top